AUTL Autolus Therapeutics plc

+0.09  (+1%)
Previous Close 16.01
Open 16.18
Price To Book 3.33
Market Cap 724,136,800
Shares 44,977,441
Volume 51,929
Short Ratio
Av. Daily Volume 124,341

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data due 1Q 2020.
T-cell lymphoma
Phase 1/2 data update due 3Q 2019.
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1/2 trial initiated 3Q 2017. Phase 1 part of trial to be completed 4Q 2019.
Relapsed or refractory multiple myeloma
Phase 2 trial to be initiated 2H 2019.
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
T-cell lymphoma
Phase 2 part of trial to be initiated 2H 2019.
Acute Lymphoblastic Leukemia

Latest News

  1. Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher
  2. Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
  3. Autolus Therapeutics Plc to Host Earnings Call
  4. Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
  5. Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
  6. Is Autolus Therapeutics plc (AUTL) A Good Stock To Buy?
  7. Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
  8. Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
  9. What Kind Of Shareholder Owns Most Autolus Therapeutics plc (NASDAQ:AUTL) Stock?
  10. Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
  11. Autolus Announces Pricing of Public Offering
  12. Autolus Announces Proposed Public Offering in the United States
  13. Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR
  14. Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
  15. Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
  16. Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
  17. Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
  18. Autolus Therapeutics to Host R&D Day on March 26, 2019
  19. Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
  20. Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019